MARKET NEWS

Translate Bio Expands Patent Portfolio With Newly Issued US Patent Relating to its mRNA Therapeutics Platform
RedHill Biopharma Announces Positive Top-Line Results From Confirmatory Phase 3 Study
MilliporeSigma Signs Exclusive Agreement With BioDuro
Sienna Biopharmaceuticals Announces Topical Drug Study Results
Melissa Unlocks Insight & Revenue With Breakthrough AI Tools for Clinics & Research Centers
GSK to Acquire Oncology Focused Biopharmaceutical Company

  FEATURED EDITORIAL

  COMPANY PROFILE

PCI Pharma Services is an integrated full service provider, a proven and trusted partner to leading companies in the global healthcare industry. We offer unparalleled expertise and experience in taking compounds from the earliest stages of development through to successful commercialization, delivering speed-to-market and commercial success for our customers. Our core services support each stage of the product lifecycle, including drug development, clinical trial supply, commercial launch and ongoing commercial supply. We partner with clients in providing innovative technologies, flexible solutions, and an integrated supply network supporting lifesaving medicines destined to over 100 countries around the world. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Cartridge Filling: Combination of Features That Can Help Gain a Competitive Edge

Cartridge Filling: Combination of Features That Can Help Gain a Competitive Edge

By 2050, it is projected that the proportion of people aged 65 and older will be more than double that of children aged 5. This global phenomenon is also leading to an increasing number of people suffering from chronic diseases, such as diabetes and osteoporosis.

Domain Therapeutics Signs R&D Collaboration & License Agreement With Boehringer Ingelheim

Domain Therapeutics Signs R&D Collaboration & License Agreement With Boehringer Ingelheim

Domain Therapeutics recently announced announces a multi-target drug discovery collaboration and licensing agreement with Boehringer Ingelheim on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.

Catalent Invests  Million to Expand Biologics Packaging Capabilities Following 20th Drug Approval

Catalent Invests $14 Million to Expand Biologics Packaging Capabilities Following 20th Drug Approval

Catalent Pharma Solutions recently announced that following the site’s 20th commercial product approval, it is investing nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington, IN, biologics manufacturing facility.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

December 19 – Parenteral Contract Manufacturing
January 9 – Capsules